dyslipidemia
Conditions
Interventions
Administration of pravastatin
Administration of ezetimibe
Sponsors
National Defense Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Dyslipidemic patients whose LDL-C levels did not reach those recommended by Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2) Outpatients 3) Subjects who gave written informed consent
Exclusion criteria
Exclusion criteria: 1) Allergy against pravastatin or ezetimibe 2) Poor-controlled diabetes (HbA1c>10.0 %) 3) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 4) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits. 5) End stage renal disease 6) Symptomatic (NYHA III or IV) congestive heart failure 7) Malignancies or other diseases with poor prognosis 8) Pregnant 9) Subjects whose doctor in charge do not agree to join the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1) inflammatory molecules (CRP, TNFa, MCP-1, S100 proteins) in blood and white blood cells (2) Flow-mediated vasodilation in brachial artery | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) serum lipids (2) diabetic parameters (3) markers of obesity (4) markers of oxidative stress (5) maekers of chronic kidney diseases/renal injury (6) urate in serum/urine (7) adiposity (8) blood pressures and pulse raate | — |
Countries
Japan
Contacts
Public ContactMakoto Ayaori
National Defense Medical College Department of Internal Medicine
Outcome results
None listed